Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04135794

Magnetic Resonance-Guided Adaptive Radiotherapy (MRgART) Using an Integrated Magnetic Resonance Linear Accelerator (MRL)

This study is being done to help further understand how MR-guided adaptive RT in conjunction with the Integrated Magnetic Resonance Linear Accelerator (MRL) can improve patient outcomes. This study will include participants who will be receiving radiotherapy using the MRL machine to target their cancer more precisely. Participants will be asked to have a few extra MR scans taken during their RT planning and to complete a few quality of life questionnaires.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients 18 years or older with a diagnosis of cancer, regardless of clinical site or stage
  • Planned to receive a course of MR-guided adaptive RT using the MRL
  • Ability to provide informed consent

Exclusion criteria

  • Patients under 18 years old

Treatment and study plan

Primary outcomes

  1. Local, regional and distant tumor control rates

    Time frame: Up to 5 years post-radiotherapy

    Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.

  2. Disease-free and overall survival rates

    Time frame: Up to 5 years post-radiotherapy

    Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.

  3. Complication rates measured using the Common Toxicity Criteria for Adverse Events

    Time frame: Within 3 months of completing treatment

    Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.

Secondary outcomes

  1. Patient experience and anxiety related to MR imaging and adaptive RT with the MR

    Time frame: Immediately after first MRL treatment visit

    Evaluate the patient experience during adaptive RT with the MRL using the Magnetic Resonance Imaging-Anxiety Questionnaire (MRI-AQ) which measures patient anxiety and tolerability of MR-related procedures

  2. Patient experience and anxiety related to MR imaging and adaptive RT with the MR

    Time frame: Immediately after last MRL treatment visit

    Evaluate the patient experience during adaptive RT with the MRL using the EORTC satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7)

  3. Patient experience and anxiety related to MR imaging and adaptive RT with the MR

    Time frame: d prior to starting treatment with the MRL, immediately after the last MRL treatment, at the first follow-up visit and annually thereafter during follow-up (up to 5 years post treatment)

    Evaluate the patient experience during adaptive RT with the MRL using -The EORTC QLQ C30 quality of life questionnaire

  4. Patient experience and anxiety related to MR imaging and adaptive RT with the MR

    Time frame: each ambulatory care and radiation treatment review clinic visit (up to 5 years post treatment)

    Evaluate the patient experience during adaptive RT with the MRL using complete the Edmonton Symptom Assessment Scale revised version (ESAS-r)

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Registry information

Acronym: MRL1

Important dates

Study start
2019
Primary completion
2027
Study completion
2027
First posted
Oct 23, 2019
Registry last updated
Mar 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.